Researchers at the University of California, Davis, have developed an investigational brain-computer interface that holds promise for restoring the voices of people who have lost the ability to speak due to neurological conditions.
A team of scientists and biomedical engineers developing pioneering technology designed to treat threatened miscarriage has secured 1 million GBP in Invention for Innovation (i4i) funding from the National Institute for Health and Care Research (NIHR) for its first clinical trial.
Mediplus has announced the release of new sizes of the POPY (Pelvic Organ Prolapse pessary) product range. The company is introducing five additional sizes to complement its existing products, offering a more precise fit and enhanced treatment options for women suffering from pelvic organ prolapse.
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA’s marketing authorization decision in early-stage breast cancer
Researchers at ETH Zurich have developed the first technology that is able to recognize biomarkers in menstrual blood—directly in sanitary towels. MenstruAI promises a simple, non-invasive method for recording health data in everyday life.
Soft, comfortable wearable device takes the guesswork out of breastfeeding
Women can now collect their own sample from the privacy of home, no speculum required, and mail it to a certified lab to be tested on the same test as the doctor’s office, with the same accuracy.
GE HealthCare (Nasdaq: GEHC) announced today that it launched its Invenia automated breast ultrasound (ABUS) premium offering.
FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD’s efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.
A small but powerful invention could soon make life in the NICU easier for the tiniest patients.